What is the starting dose of Ursodeoxycholic acid for treating intrahepatic cholestasis of pregnancy?

Ursodeoxycholic acid (UDCA) is commonly used in treating intrahepatic cholestasis of pregnancy (ICP), a condition that can lead to significant maternal and fetal complications. The standard starting dose for UDCA in the management of ICP is typically 300 mg administered twice daily. This dosage has been established as effective in alleviating the symptoms associated with the condition, such as itching, and in improving liver function tests.

Starting treatment at 300 mg twice daily is optimal as it balances efficacy and safety. This dosing helps to maintain therapeutic levels of the drug in the system while minimizing potential side effects. It is essential to regularly monitor the patient's response to the treatment and make adjustments as necessary, which can include increasing the dosage if warranted. This approach helps in managing the symptoms and potentially improving outcomes for the mother and the fetus.

The importance of using an appropriate starting dose cannot be overstated, particularly in a sensitive population like pregnant individuals, where both maternal health and fetal well-being are of utmost concern.